FMP
Inhibrx Biosciences, Inc.
INBX
NASDAQ
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
14.1 USD
-0.05 (-0.355%)
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
3.22B
3.08B
3.34B
3.8B
4.13B
4.41B
4.7B
5.02B
5.35B
5.71B
212.7M
245M
369.7M
252.2M
256.3M
339.29M
361.95M
386.12M
411.91M
439.41M
-167.6M
-104.5M
-94M
-150.3M
-184.9M
-174.99M
-186.68M
-199.14M
-212.44M
-226.63M
45.1M
140.5M
275.7M
101.9M
71.4M
164.3M
175.27M
186.98M
199.46M
212.79M
5.59
5.59
5.59
5.59
5.59
155.6M
157.21M
158.83M
160.47M
162.12M
794.24M